Last updated: August 28, 2026
Clemastine fumarate is a mature, low-cost antihistamine with limited pharmaceutical growth potential. Its commercial market is driven by generic and private-label allergy products rather than branded innovation. The drug has no meaningful biosimilar exposure, no identifiable active patent barrier supporting exclusivity, and no publicly reported standalone revenue stream from major manufacturers. Future value depends on low-cost over-the-counter distribution, supply reliability, and potential repurposing in multiple sclerosis, not on conventional prescription-drug pricing.
What is clemastine fumarate and how is it marketed?
Clemastine fumarate is an oral first-generation H1 antihistamine used to relieve symptoms of allergic rhinitis, including sneezing, rhinorrhea, and itchy or watery eyes. It is sedating and has anticholinergic effects that limit its use relative to newer agents such as loratadine, cetirizine, and fexofenadine.
The drug has been marketed in the United States under the Tavist brand and through generic and store-brand products. Typical adult products contain clemastine fumarate equivalent to 1.34 mg of clemastine per tablet, with a lower-strength formulation historically marketed as Tavist-1. FDA labeling identifies drowsiness as a key warning and cautions against alcohol, sedatives, and driving until the individual response is known (U.S. Food and Drug Administration, n.d.-a).
| Attribute |
Clemastine fumarate |
| Drug class |
First-generation H1 antihistamine |
| Primary use |
Allergy and hay fever symptom relief |
| Common route |
Oral tablet |
| Typical OTC strength |
1.34 mg clemastine fumarate per tablet |
| Sedation risk |
High relative to second-generation antihistamines |
| Regulatory status |
OTC and legacy prescription-market history |
| Biosimilar exposure |
None |
| Current commercial profile |
Mature generic and private-label market |
Clemastine should be distinguished from clemastine free base. Commercial products generally state the fumarate salt amount, while pharmacological references may report the equivalent clemastine content.
What is the FDA regulatory status of clemastine fumarate?
Clemastine fumarate is an established active ingredient with a long history of U.S. marketing. Its allergy indication is governed primarily by the FDA’s OTC regulatory framework rather than by a modern branded prescription launch strategy.
The FDA’s OTC monograph system permits certain antihistamine active ingredients and dosage forms to be marketed without an individual product approval when the product satisfies applicable conditions. The FDA’s final monograph framework for antihistamine drug products includes clemastine fumarate among recognized ingredients and establishes labeling and dosage requirements (U.S. Food and Drug Administration, 2022).
Is clemastine fumarate approved for multiple sclerosis?
No. Clemastine fumarate is not FDA-approved as a multiple sclerosis therapy.
The ReBUILD clinical trial evaluated clemastine fumarate as a potential remyelinating treatment in patients with multiple sclerosis. The trial reported an improvement in an optic-nerve conduction measure, supporting further investigation of the mechanism, but it did not create an FDA-approved multiple sclerosis indication (Green et al., 2017).
The MS research program creates a potential development option, not a current commercial indication. A sponsor seeking approval would need to establish an acceptable benefit-risk profile, demonstrate clinical benefit in an appropriate trial, and address the drug’s sedation and anticholinergic liabilities.
When does clemastine fumarate lose exclusivity?
Clemastine fumarate lost practical market exclusivity decades ago. The original branded product and early prescription approvals are legacy assets, and the active ingredient is available through generic and OTC channels.
| Exclusivity category |
Current position |
| New chemical entity exclusivity |
Expired |
| Original branded exclusivity |
Expired |
| Active formulation exclusivity |
No material barrier identified |
| Method-of-use exclusivity |
No approved MS exclusivity |
| OTC monograph protection |
Regulatory compliance pathway, not commercial exclusivity |
| Orphan exclusivity |
None identified |
| Biosimilar exclusivity |
Not applicable |
The commercially relevant question is therefore not when exclusivity expires, but whether a manufacturer can obtain sufficient volume and margin in a crowded allergy market.
What patents protect clemastine fumarate?
No active U.S. patent estate is publicly apparent that would prevent ordinary generic or OTC marketing of clemastine fumarate for its established allergy use. The original compound, salt, and basic oral-use concepts are longstanding. Any historic composition or use patents associated with the original development period would have expired.
Are there formulation patents for clemastine fumarate?
The market has limited formulation complexity. Standard tablets and oral dosage forms do not require advanced delivery technology. Potential formulation concepts could include extended release, pediatric presentations, orally disintegrating tablets, combination products, or abuse-deterrent and sedation-mitigating designs. No such concept has created a widely recognized current U.S. exclusivity position for clemastine fumarate.
A new formulation could receive patent protection if it satisfied novelty, non-obviousness, written-description, and enablement requirements. Patentability would not guarantee commercial value because the underlying antihistamine market is highly price sensitive.
Are there method-of-use patents for clemastine fumarate in multiple sclerosis?
The ReBUILD study created scientific interest in remyelination, but clinical-trial evidence alone does not establish an enforceable market monopoly. A sponsor could pursue patents covering a specific dosing regimen, patient population, biomarker, or remyelination use. Any such patents would require a valid issued claim and would face validity and infringement scrutiny.
No FDA-approved clemastine fumarate MS product currently appears to have an Orange Book-listed method-of-use patent. The absence of an approved MS indication also limits the relevance of conventional Orange Book use-code analysis.
What is the Orange Book status of clemastine fumarate?
The Orange Book is most relevant to approved prescription drug products and their listed patents and exclusivity. Clemastine fumarate’s current commercial center of gravity is OTC and generic distribution, which reduces the importance of Orange Book patent listings.
Legacy prescription approvals may appear in historical FDA records or discontinued-product databases, but a historical listing does not create current market exclusivity. OTC monograph products generally do not receive the same patent-listing and Paragraph IV framework used for an actively marketed NDA product.
The practical Orange Book conclusion is that clemastine fumarate does not have a current branded patent position comparable to newer prescription antihistamines or specialty drugs.
How many patents cover clemastine fumarate?
There is no commercially meaningful count of active U.S. patents that blocks routine clemastine fumarate allergy products. Historic patents may exist across the compound’s development history, but they do not provide current exclusivity if expired.
Patent-count analysis should separate:
- Expired compound and salt patents.
- Expired original tablet and dosing patents.
- Any later formulation patents.
- Research-stage method-of-use patents.
- Patents that are actually listed against an approved product.
For clemastine fumarate, the first category dominates the historical record, while the fourth category is the principal area of future interest.
Which companies are challenging clemastine fumarate exclusivity?
Clemastine fumarate is not being challenged through a high-profile current Paragraph IV campaign. The market has already transitioned to ordinary generic and private-label competition.
The relevant competitors are manufacturers and retailers selling low-cost antihistamine products, including:
- Generic-drug manufacturers.
- Contract manufacturers and OTC suppliers.
- Pharmacy and mass-retail private-label brands.
- Competing antihistamine producers marketing cetirizine, loratadine, fexofenadine, diphenhydramine, and chlorpheniramine.
The primary competitive pressure comes from therapeutic substitution rather than patent litigation. Second-generation antihistamines have less sedation and are more attractive for routine daytime use.
What patent litigation affects clemastine fumarate?
No major active U.S. patent litigation materially affecting the ordinary clemastine fumarate market is publicly prominent. The absence of litigation reflects the drug’s age, low unit economics, and lack of a high-value patent estate.
What settlement agreements involve clemastine fumarate?
No material current Hatch-Waxman settlement agreement involving clemastine fumarate is publicly established as a driver of market access. This differs from newer branded drugs, where patent settlements can delay generic entry and preserve billions of dollars in annual sales.
Any historic disputes would have limited commercial relevance unless they involved an unexpired formulation or an approved new indication. The established allergy market does not appear to depend on such an agreement.
How does clemastine fumarate compare with competing antihistamines?
Clemastine competes on price and availability but generally loses on tolerability and convenience.
| Drug |
Generation |
Sedation profile |
Typical market position |
Competitive effect on clemastine |
| Clemastine |
First |
High |
Low-cost legacy OTC |
Baseline generic option |
| Diphenhydramine |
First |
High |
OTC allergy and sleep products |
Direct low-cost substitute |
| Chlorpheniramine |
First |
Moderate to high |
Legacy OTC products |
Price competitor |
| Cetirizine |
Second |
Lower, but possible |
High-volume allergy brand and generic |
Strong substitution pressure |
| Loratadine |
Second |
Low |
Broad OTC and private-label use |
Strong substitution pressure |
| Fexofenadine |
Second |
Low |
Premium non-sedating OTC segment |
Strong substitution pressure |
Clemastine retains demand among consumers seeking an established product and among retailers maintaining legacy assortment. Its sedation profile limits physician preference and daytime adherence.
What is the financial trajectory for clemastine fumarate?
Clemastine fumarate has a mature, low-margin financial profile. Public companies generally do not report clemastine revenue separately because sales are immaterial relative to portfolio products. Revenue is distributed across private-label contracts, generic portfolios, pharmacy sales, and OTC channels.
The commercial trajectory has four phases:
Original branded phase
The original Tavist franchise benefited from brand recognition and prescription-market positioning. That phase ended as generic antihistamines and newer agents expanded.
Generic substitution phase
After loss of exclusivity, price competition reduced the value of branded clemastine. Manufacturers could compete with limited clinical differentiation because the active ingredient and basic dosage form were established.
OTC commoditization phase
The market moved toward private-label and retailer-controlled products. Marketing shifted from physician promotion to shelf placement, retailer distribution, and price.
Stable maintenance phase
Current demand is likely stable but modest. It is supported by recurring seasonal allergy use, legacy consumer familiarity, and low manufacturing complexity. Growth is constrained by substitution toward second-generation antihistamines and declining physician use of sedating agents.
No reliable public source provides a standalone global clemastine fumarate revenue figure. Manufacturer filings typically aggregate OTC and generic sales across broader categories. As a result, precise market-size or annual-growth claims would not be decision-grade.
What generic launch risks exist for clemastine fumarate?
Generic launch risk is low from a patent perspective and moderate from an operational perspective.
Patent and regulatory risk
A conventional generic or OTC product does not face a meaningful compound patent barrier. The principal requirements are compliance with FDA monograph conditions, manufacturing controls, labeling, quality standards, and product registration obligations.
Commercial risk
Commercial returns are limited because:
- Retail pricing is compressed.
- Several antihistamines are interchangeable from the consumer’s perspective.
- Retailers can switch suppliers.
- Seasonal demand creates inventory risk.
- Brand loyalty is weaker than for newer prescription therapies.
Supply-chain risk
The most relevant barrier is manufacturing execution. API availability, approved manufacturing sites, quality deviations, and retailer qualification can affect supply more than intellectual property. A supplier with a reliable API source and low-cost tablet production may compete effectively without owning proprietary technology.
Does clemastine fumarate have biosimilar risk?
No. Clemastine fumarate is a small-molecule chemical drug, not a biologic. It is exposed to ordinary generic competition rather than biosimilar competition.
The distinction matters commercially. Generic entry is governed by small-molecule approval pathways, while biosimilar competition involves biologic comparability, interchangeability, reference-product exclusivity, and more complex manufacturing requirements. None of those biologic barriers apply to clemastine fumarate.
Are there licensing deals for clemastine fumarate?
No major current licensing transaction appears to drive the commercial market for clemastine fumarate. Its established allergy use is broadly available, and the product is not controlled by a high-value originator license.
The main licensing opportunity would involve repurposing for remyelination or another specialty indication. Such a transaction would require more than historical clinical evidence. A sponsor would need a development plan, regulatory strategy, patent position, and evidence that the commercial opportunity can support clinical-trial costs.
What geographic markets are relevant?
The United States is a mature OTC and generic market. International markets may use different brand names, prescription classifications, dosage strengths, or combination products. Regulatory status varies by country, and a U.S. OTC position does not automatically establish marketing authorization elsewhere.
Geographic commercial value is concentrated in markets with:
- Established allergy-drug consumption.
- Retail pharmacy distribution.
- Local generic manufacturing.
- Regulatory recognition of clemastine as an OTC or established medicine.
The absence of strong IP protection makes local registration, supply cost, and channel access more important than territorial patent rights.
How strong is the clemastine fumarate patent estate?
The patent estate is weak for the established allergy indication and potentially more relevant for a future specialty indication.
| Patent-estate factor |
Assessment |
| Compound protection |
Expired |
| Salt protection |
Expired or commercially immaterial |
| Basic oral formulation |
Weak and historically mature |
| OTC allergy use |
No meaningful current exclusivity |
| MS repurposing |
Potentially protectable, but not approved |
| Manufacturing barriers |
Low to moderate |
| Freedom to operate for standard tablets |
Generally favorable |
| Pricing power |
Low |
A credible investment thesis would therefore need to center on clinical repurposing, a differentiated formulation, or a specialized distribution strategy. A standard generic allergy tablet does not offer a strong IP-based return profile.
Key Takeaways
- Clemastine fumarate is a mature first-generation antihistamine sold primarily through generic, OTC, and private-label channels.
- Original brand and compound exclusivity have expired.
- No material active U.S. patent barrier is apparent for standard allergy tablets.
- The drug has no biosimilar risk because it is a small-molecule chemical product.
- Paragraph IV litigation and settlement activity are not significant current market drivers.
- FDA regulation is primarily relevant through OTC monograph compliance and generic manufacturing requirements.
- Revenue is not separately disclosed by major public companies, preventing a reliable standalone market-size estimate.
- Financial growth is constrained by low pricing, retailer substitution, and competition from cetirizine, loratadine, and fexofenadine.
- The main strategic upside is potential repurposing in multiple sclerosis or another specialty indication.
- Any specialty opportunity would require new clinical evidence, a defensible patent strategy, and FDA approval.
FAQs
Is clemastine fumarate still commercially available?
Yes. Availability varies by country, retailer, product strength, and manufacturer. It is generally encountered as a generic or private-label allergy product rather than as a premium branded medicine.
Can a company obtain new patents on clemastine fumarate?
Potentially. New patents could target a novel formulation, dosing regimen, patient population, combination, or therapeutic use. The claims would need to satisfy patentability requirements and would not restore expired compound exclusivity.
Is clemastine fumarate used off-label for multiple sclerosis?
It has been investigated as a remyelinating agent in multiple sclerosis, but it is not FDA-approved for that indication. Clinical use outside the approved allergy indication would be off-label.
Why has clemastine fumarate not achieved premium pricing?
The active ingredient is old, generic competition is available, the dosage form is relatively simple, and consumers can substitute other antihistamines. Its sedating profile also reduces differentiation in routine allergy treatment.
What would increase the commercial value of clemastine fumarate?
The largest potential value driver would be regulatory approval for a new specialty indication supported by clinical efficacy and protected by valid method-of-use or formulation patents. Without that development, the product remains a low-margin mature OTC medicine.
References
-
Green, A. J., Gelfand, J. M., Cree, B. A. C., Bevan, C., Vigil, S. A., Hagan, S., ... Cross, A. H. (2017). Clemastine fumarate as a remyelinating therapy for multiple sclerosis: ReBUILD, a randomised, controlled, double-blind, crossover trial. The Lancet, 390(10111), 2481-2489. https://doi.org/10.1016/S0140-6736(17)32346-2
-
U.S. Food and Drug Administration. (2022). Antihistamine drug products for over-the-counter human use: Final monograph. Code of Federal Regulations, 21 C.F.R. Part 341. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341
-
U.S. Food and Drug Administration. (n.d.-a). Clemastine fumarate tablet labeling. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
